Aequus Pharmaceuticals Inc. (AQSZF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAequus Pharmaceuticals Inc. (AQSZF) trades at $0.0007. Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on developing and commercializing drugs in neurology, ophthalmology, and transplantation. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for AQSZF: AQSZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AQSZF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
AQSZF: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Aequus Pharmaceuticals Inc. (AQSZF) Healthcare & Pipeline Overview
Aequus Pharmaceuticals Inc., based in Canada, specializes in developing and commercializing drugs for neurology, ophthalmology, and transplantation. With products like Vistitan and Evolve, alongside a pipeline of extended-release and cannabinoid-based therapies, Aequus operates in the competitive specialty pharmaceutical market, collaborating with partners like Sandoz and Supernus.
What Is the Investment Thesis for AQSZF?
Aequus Pharmaceuticals operates in niche healthcare markets, offering potential for growth through its existing product portfolio and development pipeline. The company's focus on ophthalmology, neurology, and transplantation provides diversification. Key value drivers include successful commercialization of pipeline products like Topiramate XR and AQS1304, expansion of existing product sales, and strategic partnerships. However, the company's negative profit margin of -71.5% and small market capitalization present risks. Investors should monitor the progress of clinical trials, regulatory approvals, and the company's ability to achieve profitability. The company's beta of -0.28 suggests low volatility relative to the market.
Based on FMP financials and quantitative analysis
AQSZF Key Highlights
Aequus Pharmaceuticals focuses on specialty pharmaceuticals within neurology, ophthalmology, and transplantation.
- The company markets Vistitan for glaucoma, addressing a significant market need.
- Aequus has a development pipeline including extended-release anti-epileptic drugs and cannabinoid-based therapeutics.
- The company maintains strategic collaborations with Sandoz, Supernus, and Medicom Healthcare.
- Aequus Pharmaceuticals has a gross margin of 53.3% indicating potential profitability from its products.
Who Are AQSZF's Competitors?
AQSZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| TAK Takeda Pharmaceutical Company Limited | $18.11 | -0.55% | $57.6B | 635-pillar |
| TEVA Teva Pharmaceutical Industries Limited | $36.65 | +0.84% | $42.7B | 605-pillar |
| HLN Haleon plc | $9.22 | -0.11% | $40.6B | 775-pillar |
| ZTS Zoetis Inc. | $72.89 | -0.57% | $30.6B | 855-pillar |
| VTRS Viatris Inc. | $16.49 | +0.67% | $19.2B | 335-pillar |
| ELAN Elanco Animal Health Incorporated | $22.86 | -2.93% | $11.4B | 335-pillar |
| RDY Dr. Reddy's Laboratories Limited | $12.01 | +2.52% | $10.0B | 795-pillar |
| LNTH Lantheus Holdings, Inc. | $100.50 | +0.11% | $6.54B | 905-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AQSZF's Key Strengths?
Focus on niche therapeutic areas.
- Existing product portfolio with established revenue streams.
- Strategic partnerships with larger pharmaceutical companies.
- Development pipeline of new products.
What Are AQSZF's Weaknesses?
Small market capitalization.
- Negative profit margin.
- Limited geographic reach.
- Reliance on partnerships for distribution.
What Could Drive AQSZF Stock Higher?
Clinical trial results for Topiramate XR and Oxcarbazepine XR extended-release tablets for epilepsy.
- Regulatory approval decisions for AQS1303 for the treatment of nausea and vomiting of pregnancy.
- Potential new partnerships for distribution or co-development of products.
- Expansion of the Evolve dry eye product line into new markets.
- Continued growth in sales of Vistitan for glaucoma.
What Are the Key Risks for AQSZF?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for development-stage products.
- Regulatory delays or rejections for new product approvals.
- Increased competition from larger pharmaceutical companies.
- Pricing pressures and generic drug penetration.
- Dependence on partnerships for distribution and commercialization.
What Are the Growth Opportunities for AQSZF?
- Expansion of Ophthalmology Product Line: Aequus can expand its Evolve dry eye product line and Vistitan sales by targeting a larger market share within the growing ophthalmology sector. The global dry eye syndrome market is projected to reach $6.5 billion by 2028, offering a substantial opportunity for Aequus to increase revenue through innovative formulations and expanded distribution channels. This expansion can be realized within the next 2-3 years through strategic marketing and partnerships.
- Advancement of Epilepsy Pipeline: The development and commercialization of Topiramate XR and Oxcarbazepine XR extended-release oral tablets for epilepsy represent a significant growth opportunity. The global epilepsy market is expected to reach $11 billion by 2027. Successful clinical trials and regulatory approvals could position Aequus to capture a portion of this market, potentially generating substantial revenue streams starting in 2028.
- Commercialization of Cannabinoid Therapeutics: Aequus's AQS1304, a cannabinoid-based therapeutic for neurological disorders, presents a novel growth avenue. The increasing acceptance of cannabinoid-based therapies for various neurological conditions offers a promising market. The global cannabinoid market is projected to reach $47 billion by 2027. Aequus could potentially launch this product within the next 3-5 years, pending regulatory approvals and clinical trial outcomes.
- Strategic Partnerships and Collaborations: Aequus can leverage strategic partnerships to expand its market reach and product portfolio. Collaborations with companies like Sandoz and Supernus have already proven beneficial. Seeking additional partnerships for distribution, co-development, or licensing agreements can accelerate growth and reduce risk. These partnerships can be forged within the next 1-2 years, enhancing Aequus's market presence and innovation capabilities.
- Geographic Expansion Beyond Canada: While currently focused on the Canadian market, Aequus can explore opportunities for geographic expansion into other regions, such as the United States or Europe. This expansion could involve partnering with local distributors or establishing a direct presence. The global pharmaceutical market offers vast opportunities, and strategic geographic expansion can significantly increase Aequus's revenue base over the next 3-5 years.
What Opportunities Does AQSZF Have?
- Expansion into new therapeutic areas.
- Geographic expansion into new markets.
- Acquisition of new products or technologies.
- Increased demand for specialty pharmaceuticals.
What Are AQSZF's Competitive Advantages?
- Specialty Focus: Niche therapeutic areas provide less competition.
- Product Portfolio: Diversified product offerings across multiple therapeutic areas.
- Strategic Partnerships: Collaborations with established pharmaceutical companies.
- Development Pipeline: Pipeline of new products in development.
What Does AQSZF Do?
Aequus Pharmaceuticals Inc., established in 2013 and headquartered in Vancouver, Canada, is a specialty pharmaceutical company dedicated to the development and commercialization of differentiated products. The company focuses on addressing unmet needs in neurology, ophthalmology, and transplantation. Aequus markets Vistitan, an ophthalmology product used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It also offers Tacrolimus IR, an immunosuppressant used to prevent acute rejection following organ transplantation, and the Evolve line of dry eye products. In addition to its marketed products, Aequus has a pipeline of development-stage products, including Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy. The company is also developing AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy, and AQS1304, a cannabinoid-based therapeutic for neurological disorders. Aequus collaborates with Sandoz Canada, Inc. for the promotion of Vistitan, Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic drugs, and Medicom Healthcare Ltd. to focus on preservative-free therapies in ophthalmology. With a small team of 12 employees, Aequus operates primarily in the Canadian market, seeking to expand its product offerings and partnerships.
What Products and Services Does AQSZF Offer?
- Develops and commercializes specialty pharmaceutical products.
- Focuses on therapeutic areas including neurology, ophthalmology, and transplantation.
- Markets Vistitan to reduce intraocular pressure in glaucoma patients.
- Offers Tacrolimus IR for the prevention of organ rejection.
- Provides Evolve dry eye products for dry eye disease and blepharitis.
- Develops extended-release oral tablets for the treatment of epilepsy.
- Develops cannabinoid-based therapeutics for neurological disorders.
How Does AQSZF Make Money?
- Develops and acquires rights to specialty pharmaceutical products.
- Commercializes products through direct sales and marketing efforts.
- Partners with other pharmaceutical companies for distribution and promotion.
- Generates revenue through product sales and licensing agreements.
What Industry Does AQSZF Operate In?
Aequus Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and stringent regulatory requirements. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in drug delivery technologies. Companies like Aequus focus on niche therapeutic areas to differentiate themselves. The industry is also influenced by pricing pressures, generic drug penetration, and the need for continuous innovation. Aequus's collaborations and focus on specific therapeutic areas position it to capitalize on market trends.
Who Are AQSZF's Key Customers?
- Patients with glaucoma and ocular hypertension.
- Patients undergoing organ transplantation.
- Patients with dry eye disease and blepharitis.
- Patients with epilepsy and other neurological disorders.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 347 days ago
- ● No analyst coverage
- ● Reported in CAD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 59 |
| 2026-08-27 | 59 |
| 2026-08-31 | 59 |
| 2026-09-04 | 59 |
| 2026-09-08 | 59 |
| 2026-09-11 | 59 |
What changed?
The score has stayed at 59.
Over the same 19 days the stock moved -41.7%.
Financial Health
Aequus Pharmaceuticals Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Quarterly Financial Performance: Aequus Pharmaceuticals Inc.
Revenue for Aequus Pharmaceuticals Inc. came in at $182K during Q3 FY2025, a 15.4% improvement versus the preceding quarter. The company recorded net income of $267K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, AQSZF averaged $-0.00 in diluted EPS.
Key Financial Metrics
Return on equity for Aequus Pharmaceuticals Inc. stands at 9.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -14.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -99.0%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Aequus Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Douglas Glen Janzen. AQSZF has traded publicly since 2015.
AQSZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Focus on niche therapeutic areas.
- Existing product portfolio with established revenue streams.
- Strategic partnerships with larger pharmaceutical companies.
- Development pipeline of new products.
Bear Case
- Small market capitalization.
- Negative profit margin.
- Limited geographic reach.
- Reliance on partnerships for distribution.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 FY2025 | $181,549.88 | $267,170.111 | $0.0020 |
| Q2 FY2025 | $157,367.171 | -$118,201.336 | -$0.0009 |
| Q1 FY2025 | $163,370.661 | -$465,208.135 | -$0.0035 |
| Q4 FY2024 | $160,056.302 | -$157,072.225 | -$0.0012 |
Q3 FY2025 · filed 30 Sep 2025 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Converted to USD from CAD at today's rate
AQSZF Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Jan 10, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Jan 9, 2020
AQSZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AQSZF.
Price Targets
Wall Street price target analysis for AQSZF.
AQSZF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AQSZF; grades run from A+ (80-100) to F (below 30).
Leadership: Douglas Glen Janzen
CEO
Douglas Glen Janzen serves as the CEO of Aequus Pharmaceuticals Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on commercialization and business development. He has held various leadership positions in pharmaceutical companies, contributing to product launches, market access strategies, and partnership development. His expertise spans across multiple therapeutic areas, including neurology and ophthalmology. Janzen's experience positions him to lead Aequus in its growth and expansion efforts.
Track Record: Under Douglas Glen Janzen's leadership, Aequus Pharmaceuticals has focused on expanding its product portfolio and strengthening its strategic partnerships. Key milestones include the commercialization of Vistitan and the expansion of the Evolve dry eye product line. Janzen has also overseen the advancement of the company's development pipeline, including the progress of extended-release anti-epileptic drugs and cannabinoid-based therapeutics. His strategic decisions have aimed to position Aequus for sustainable growth in the specialty pharmaceutical market.
AQSZF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aequus Pharmaceuticals Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the potential for lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited Financial Disclosure: Lack of transparency due to minimal reporting requirements.
- Low Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Price Volatility: Potential for significant price swings due to limited trading activity.
- Regulatory Scrutiny: Increased risk of regulatory action due to non-compliance with reporting standards.
- Information Asymmetry: Limited access to reliable information compared to companies on major exchanges.
- Verify the company's financial statements and audit reports.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Analyze the company's cash flow and debt levels.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established Business Operations: Aequus Pharmaceuticals has been in operation since 2013.
- Product Portfolio: The company has a portfolio of marketed products and a development pipeline.
- Strategic Partnerships: Aequus has collaborations with reputable pharmaceutical companies.
- Focus on Specific Therapeutic Areas: The company specializes in neurology, ophthalmology, and transplantation.
- CEO Leadership: Douglas Glen Janzen has experience in the pharmaceutical industry.
Aequus Pharmaceuticals Inc. Healthcare Stock: Key Questions Answered
Is AQSZF a good stock?
Stock Expert AI does not rate AQSZF buy, sell or hold. Aequus Pharmaceuticals Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about AQSZF stock?
As of March 16, 2026, there is no readily available analyst consensus on AQSZF stock due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-1.01) and profit margin (-71.5%) reflect the company's current financial challenges.
What are the key factors to evaluate for AQSZF?
Evaluate AQSZF on fundamentals, analyst consensus, and risk factors. The company's beta of -0.28 suggests low volatility relative to the market. Not financial advice.
How frequently does AQSZF data refresh on this page?
AQSZF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven AQSZF's recent stock price performance?
Aequus Pharmaceuticals Inc. (AQSZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on niche therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AQSZF overvalued or undervalued right now?
Aequus Pharmaceuticals Inc. (AQSZF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of AQSZF?
Yes, most major brokerages offer fractional shares of Aequus Pharmaceuticals Inc. (AQSZF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track AQSZF's earnings and financial reports?
Aequus Pharmaceuticals Inc. (AQSZF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for AQSZF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and less reliable than data from major exchanges.